MCID: BCL006
MIFTS: 65

B-Cell Lymphomas

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for B-Cell Lymphomas

MalaCards integrated aliases for B-Cell Lymphomas:

Name: B-Cell Lymphomas 38 76 73
B-Cell Lymphoma 12 53 29 15
Lymphoma, B-Cell 53 44 40
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 55

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 44 D016393
NCIt 50 C27907 C3457
UMLS 73 C0079731

Summaries for B-Cell Lymphomas

NIH Rare Diseases : 53 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphomas, also known as b-cell lymphoma, is related to primary mediastinal b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with B-Cell Lymphomas is MIR20A (MicroRNA 20a
To identify essential target(s) of miR-17-92 in lymphomagenesis, we first transfected miR-17-92 into two genetically distinct B-cell lymphoma cell lines: Raji cells, which overexpress c-Myc, and SUDHL4 cells, which overexpress Bcl2. Raji cells transfected with miR-17-19b-1 exhibited downregulated expression Bim and a slight upregulation in Bcl2 expression. On the other hand, SUDHL4 cell transfectants showed aggressive cell growth reflecting facilitated cell cycle progression at the G1-S transition and decreased expression of CDKN1A mRNA and p21 protein (CDKN1A/p21) that was independent of p53 expression. Conversely, transfection of antisense oligonucleotides against miR-17 and miR-20a into Jeko-1 cells led to upregulation of CDKN1A/p21, resulting in decreased cell growth with G1-S arrest. Thus, CDKN1A/p21 appears to be an essential target of miR-17-92 during B-cell lymphomagenesis, which suggests the miR-17-92 polycistron has distinct targets in different B-cell lymphoma subtypes.), and among its related pathways/superpathways are Regulation of IFNA signaling and NF-kappaB Signaling. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for B-Cell Lymphomas

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 primary mediastinal b-cell lymphoma 35.5 BCL6 REL
2 nodal marginal zone b-cell lymphoma 35.4 BCL6 MALT1
3 primary cutaneous marginal zone b-cell lymphoma 35.4 BCL10 IRF4 MALT1
4 primary mediastinal large b-cell lymphoma 35.4 BCL6 FOXP1 IRF4
5 marginal zone b-cell lymphoma 35.3 BCL10 BCL6 IRF4 MALT1 MME
6 t-cell/histiocyte rich large b cell lymphoma 35.2 BCL6 MME
7 intravascular large b-cell lymphoma 35.2 BCL6 MME
8 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 35.1 BCL6 MYC
9 lymphoma, mucosa-associated lymphoid type 34.4 BCL10 BCL6 CCND1 FOXP1 IRF4 MALT1
10 splenic marginal zone lymphoma 34.1 BCL6 MALT1 PAX5
11 primary effusion lymphoma 33.8 BCL6 IRF4 MYC
12 diffuse large b-cell lymphoma 33.7 BCL10 BCL6 FOXP1 HOTAIR IRF4 MALT1
13 follicular lymphoma 33.7 BCL10 BCL6 CCND1 IRF4 MME MYC
14 reticulosarcoma 33.2 BCL6 CCND3 PAX5
15 mature b-cell neoplasm 33.0 BCL6 MME MYC PVT1
16 nodular lymphocyte predominant hodgkin lymphoma 32.0 BCL6 CCND1 PAX5
17 burkitt lymphoma 32.0 BCL6 CCND3 MME MYC PAX5 PVT1
18 angioimmunoblastic t-cell lymphoma 31.9 BCL6 MME
19 lymphoma 31.6 BCL10 BCL6 CCND1 GAS5 MALT1 MYC
20 central nervous system lymphoma 31.6 BCL6 FOXP1 MALT1
21 composite lymphoma 31.5 BCL6 PAX5
22 follicular lymphoma 1 31.5 BCL10 BCL6
23 cll/sll 31.4 CCND1 MME PAX5
24 plasmacytoma 31.4 IRF4 MYC PVT1
25 lymphoma, hodgkin, classic 31.2 BCL6 IRF4 MIR20A PAX5 PVT1
26 lung lymphoma 31.0 BCL6 MALT1 PAX5
27 leukemia, chronic lymphocytic 30.9 BCL10 BCL6 CCND1 PAX5 TP53COR1
28 lymphoma, non-hodgkin, familial 30.5 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
29 t-cell leukemia 30.3 GAS5 IRF4 MYC REL
30 mantle cell lymphoma 29.5 BCL6 CCND1 CCND3 CDKN1B GAS5 MALAT1
31 retinoblastoma 29.2 CCND1 CCND3 HOTAIR MALAT1
32 leukemia, acute myeloid 28.6 HOTAIR MALAT1 MME MYC TUG1
33 small cell cancer of the lung 28.3 HOTAIR MALAT1 MYC TUG1
34 squamous cell carcinoma 28.0 CCND1 CDKN1B HOTAIR MALAT1 TUG1
35 thyroid cancer, nonmedullary, 1 27.9 GAS5 HOTAIR MALAT1 PVT1
36 nasopharyngeal carcinoma 27.4 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
37 lung cancer susceptibility 3 27.4 CCND1 GAS5 HOTAIR MALAT1 TUG1
38 glioblastoma 26.9 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MYC
39 myeloma, multiple 26.7 CCND1 CCND3 GAS5 HOTAIR IRF4 MALAT1
40 bladder cancer 26.5 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
41 glioma 25.5 CCND1 GAS5 HOTAIR MALAT1 MIR17 MIR20A
42 hepatocellular carcinoma 25.4 CCND1 GAS5 HOTAIR MALAT1 MIR20A MYC
43 gastric cancer 25.1 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MIR20A
44 breast cancer 25.1 CCND1 CCND3 CDKN1B GAS5 HOTAIR MALAT1
45 lung cancer 24.9 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MIR20A
46 colorectal cancer 24.5 BCL10 CCND1 CDKN1B GAS5 HOTAIR MALAT1
47 alk-positive large b-cell lymphoma 12.5
48 relapsed/refractory diffuse large b-cell lymphoma 12.4
49 splenic diffuse red pulp small b-cell lymphoma 12.4
50 primary cutaneous diffuse large b-cell lymphoma, leg type 12.4

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to B-Cell Lymphomas

Symptoms & Phenotypes for B-Cell Lymphomas

MGI Mouse Phenotypes related to B-Cell Lymphomas:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
2 immune system MP:0005387 9.7 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
3 neoplasm MP:0002006 9.1 MYC PAX5 CCND1 CCND3 CDKN1B IRF4

Drugs & Therapeutics for B-Cell Lymphomas

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
5
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
6
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
7
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
8
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
9
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for B-Cell Lymphomas (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 588)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
8
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
16
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
17
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754
19
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
20
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
21
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
22
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
23
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
26
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1177-87-3
47 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1925)
# Name Status NCT ID Phase Drugs
1 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
5 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
6 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
7 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
8 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
9 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Recruiting NCT03229200 Phase 4 Ibrutinib
10 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
11 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
12 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4 Tenofovir
13 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
14 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
15 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
16 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
17 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
18 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
19 MabionCD20® Compared to MabThera® in Lymphoma Patients Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
20 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
21 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
22 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
23 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
24 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
25 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
26 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
27 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
28 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
29 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
30 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
31 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
32 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
33 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
34 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
35 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
36 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
37 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
38 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
39 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
40 Treatment of Mature B-cell Lymphoma/Leukaemia Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
41 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
42 A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) Completed NCT01287741 Phase 3 Rituximab;Obinutuzumab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
43 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
44 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
45 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
46 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
47 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
48 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
49 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Completed NCT00144755 Phase 3 Darbepoetin alfa
50 ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphomas

Genetic tests related to B-Cell Lymphomas:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 29

Anatomical Context for B-Cell Lymphomas

MalaCards organs/tissues related to B-Cell Lymphomas:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Lymph Node, Liver

Publications for B-Cell Lymphomas

Articles related to B-Cell Lymphomas:

(show top 50) (show all 4281)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. ( 29662618 )
2018
3
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
4
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
5
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
6
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. ( 29845599 )
2018
7
Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. ( 29721249 )
2018
8
Ulcerated necrobiosis lipoidica: A cutaneous granulomatous reaction associated with systemic B-cell lymphoma. ( 29770790 )
2018
9
Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas ( 29801398 )
2018
10
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( 29193018 )
2018
11
Orthodeoxia as a presentation of intravascular large B cell lymphoma. ( 29796279 )
2018
12
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. ( 29332711 )
2018
13
Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. ( 29956350 )
2018
14
Massive splenomegaly due to B-cell lymphoma: A case report. ( 29885916 )
2018
15
Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. ( 29966970 )
2018
16
Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness. ( 29979613 )
2018
17
Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review. ( 29519992 )
2018
18
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
19
High frequency and prognostic value of<i>MYD88</i>L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. ( 29403563 )
2018
20
Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis. ( 29854538 )
2018
21
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making. ( 29748435 )
2018
22
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. ( 29720487 )
2018
23
Serial chest CT findings of intravascular large B-cell lymphoma of the lungs. ( 29707378 )
2018
24
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. ( 29271084 )
2018
25
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. ( 29419431 )
2018
26
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. ( 29899297 )
2018
27
CAR T cell therapy for B-cell lymphomas. ( 29909914 )
2018
28
Composite cutaneous lymphoma of diffuse large B-cell lymphoma-leg type and subcutaneous panniculitis-like T-cell lymphoma. ( 29851123 )
2018
29
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
30
The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ( 29623003 )
2018
31
Spontaneous Regression of Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. ( 29508000 )
2018
32
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. ( 29978453 )
2018
33
Human herpesvirus-encoded kinase induces B cell lymphomas in vivo. ( 29733294 )
2018
34
Small Cell Variant of Intravascular Large B-Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. ( 29850589 )
2018
35
Epstein-Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas. ( 29937761 )
2018
36
Meningeal marginal zone B-cell lymphoma: The meningioma trap. ( 29331570 )
2018
37
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani etA al. ( 29528099 )
2018
38
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
39
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
40
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
41
EBV-positive B-cell lymphoma manifestation of the liver in an infant with RAG1 severe combined immunodeficiency disease. ( 29856523 )
2018
42
Isolated superior oblique muscle extranodal marginal zone B cell lymphoma: case report. ( 29755275 )
2018
43
De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas? ( 29399573 )
2018
44
Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment. ( 29719020 )
2018
45
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
46
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
47
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
48
Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare Case. ( 29780139 )
2018
49
Teaching NeuroImages: Presentation of diffuse large B-cell lymphoma with bilateral sequential oculomotor neuropathy. ( 29967210 )
2018
50
Lymphomatoid Papulosis (LyP) Associated with Diffuse Large B-cell Lymphoma and Cutaneous Anaplastic Large Cell Lymphoma: LyP as a Haematological Malignancy-related Dermadrome. ( 29796688 )
2018

Variations for B-Cell Lymphomas

Cosmic variations for B-Cell Lymphomas:

9
(show top 50) (show all 82)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 4
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 4
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 4
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 4
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 4
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 4
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 4
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 4
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 4
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 4
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 4
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 4
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 4
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 4
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 4
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 4
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 4
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 4
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 4
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 4
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 4
23 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 4
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 4
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 4
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 4
31 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 4
32 COSM6986772 TRAF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 2
33 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 2
34 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 2
35 COSM44910 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 2
36 COSM4721653 RICTOR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 2
37 COSM190567 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.206T>C p.L69P 3:49368499-49368499 2
38 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 10:87933243-87933243 2
39 COSM6987562 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.331T>G p.W111G 10:87933090-87933090 2
40 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 10:87925550-87925550 2
41 COSM30627 PIK3CA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 2
42 COSM85940 MYD88 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.794T>C p.L265P 3:38141150-38141150 2
43 COSM6987557 MSH6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.493T>C p.F165L 2:47795929-47795929 2
44 COSM2006760 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.12952C>T p.Q4318* 12:49030678-49030678 2
45 COSM6987497 KDM6A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 2
46 COSM6949886 HGF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.986G>T p.W329L 7:81729659-81729659 2
47 COSM6948355 GRIN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2453C>T p.A818V 16:9768993-9768993 2
48 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 7:148811636-148811636 2
49 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 7:148811635-148811635 2
50 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2645G>A p.R882H 2:25234373-25234373 2

Expression for B-Cell Lymphomas

Search GEO for disease gene expression data for B-Cell Lymphomas.

Pathways for B-Cell Lymphomas

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.52 CCND1 CCND3 IRF4 MYC
2 12.42 BCL10 BCL6 IRF4 MALT1 PAX5 REL
3 12.36 CCND1 CDKN1B FOXP1 MIR17 MIR20A MYC
4
Show member pathways
12.33 BCL10 IRF4 MALT1 REL
5 12.27 CCND1 CCND3 CDKN1B MYC
6 12.18 CCND1 CCND3 CDKN1B REL
7 12.12 BCL6 CDKN1B MYC PAX5 REL
8
Show member pathways
12.1 CCND1 CCND3 CDKN1B MYC
9
Show member pathways
11.97 CCND1 CCND3 MYC
10 11.87 BCL6 CCND1 IRF4 MYC
11 11.85 CCND1 CDKN1B MYC
12
Show member pathways
11.82 CCND1 CCND3 CDKN1B MYC REL
13
Show member pathways
11.81 BCL10 BCL6 IRF4 MALT1 MYC REL
14 11.77 CCND1 CDKN1B MYC
15 11.74 CCND1 CCND3 CDKN1B MYC
16 11.67 CCND1 CDKN1B MYC PAX5
17 11.64 CCND3 CDKN1B MYC
18 11.61 BCL6 CCND1 CCND3 CDKN1B MYC
19 11.6 CCND3 CDKN1B MYC
20 11.58 CCND1 CDKN1B MYC
21 11.53 CCND1 CDKN1B MYC
22
Show member pathways
11.47 CCND1 CCND3 CDKN1B MIR17 MIR20A MYC
23 11.45 BCL6 MME PAX5
24
Show member pathways
11.38 CCND1 CDKN1B MYC
25 11.37 CCND1 CCND3 CDKN1B MYC
26 11.24 CCND1 CCND3 MYC
27 11.2 CCND1 CCND3 MYC REL

GO Terms for B-Cell Lymphomas

Cellular components related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.88 BCL6 CCND1 CCND3 MYC PAX5 REL
2 cytokine-mediated signaling pathway GO:0019221 9.85 BCL6 CCND1 IRF4 MYC
3 negative regulation of gene expression GO:0010629 9.76 MIR17 MIR20A MYC REL
4 G1/S transition of mitotic cell cycle GO:0000082 9.7 CCND1 CDKN1B MYC
5 response to estradiol GO:0032355 9.69 CCND1 CDKN1B MYC
6 T cell proliferation GO:0042098 9.54 CCND3 MALT1
7 response to molecule of bacterial origin GO:0002237 9.49 BCL10 MALT1
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR17 MIR20A
9 negative regulation of B cell apoptotic process GO:0002903 9.43 BCL6 FOXP1
10 response to fungus GO:0009620 9.37 BCL10 MALT1
11 positive regulation of cell cycle GO:0045787 9.33 CCND1 CDKN1B MYC
12 re-entry into mitotic cell cycle GO:0000320 9.32 CCND1 MYC
13 regulation of T cell receptor signaling pathway GO:0050856 9.26 BCL10 MALT1
14 positive regulation of pulmonary blood vessel remodeling GO:1905111 8.96 MIR17 MIR20A
15 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 8.8 CCND1 CCND3 CDKN1B

Molecular functions related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activator activity GO:0019209 9.16 BCL10 MALT1
2 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
3 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.8 CCND1 CCND3 CDKN1B

Sources for B-Cell Lymphomas

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....